Yahoo Finance Insider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX)
On July 1, 2024, Jim Wassil, Chief Operating Officer of Vaxcyte Inc (NASDAQ:PCVX), executed a sale of 3,000 shares of the company. The transaction was documented in an SEC Filing. Following this transaction, the insider now owns 210,503 shares of Vaxcyte Inc.
Vaxcyte Inc (NASDAQ:PCVX) is a biotechnology company focused on the development of vaccines for infectious diseases. The company aims to improve global health through the advancement of novel vaccines targeting a variety of bacterial and viral infections.
According to the filing, the shares were sold at a price of $76.34, valuing the transaction at approximately $229,020. This recent sale is part of a larger trend observed over the past year, where the insider has sold a total of 27,000 shares. During the same period, there have been no recorded purchases of shares by the insider.
The broader insider transaction history for Vaxcyte Inc reveals a pattern of selling activities, with 47 insider sells and no insider buys over the past year. This could be of interest to investors looking for patterns in insider behaviors.
As of the latest sale, Vaxcyte Inc (NASDAQ:PCVX) holds a market cap of approximately $8.27 billion. The stock's valuation metrics, including price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are also accessible for further financial analysis.
For those interested in the stock's fair value, the GF Value provides an estimation of its intrinsic value based on historical trading prices, financial ratios, and analysts' forecasts of future business performance.
The insider's recent transaction and the ongoing trends in insider activities at Vaxcyte Inc are crucial data points for stakeholders monitoring the company's stock and assessing its investment potential.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
